Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 2089-2096

  Li, Ning ^a,b   Sood, Sandeep ^a   Wang, Su ^a   Fang, Mingzhu ^a   Wang, Peng ^a   Sun, Zheng ^c   Yang, Chung S ^a   Chen, Xiaoxin ^a  

^a RUTGERS UNIVERSITY   (United States)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYLBENZ[A]ANTHRACENE; LIPOXYGENASE INHIBITOR; ZILEUTON;

ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER PREVENTION; CANCER TISSUE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HAMSTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYUREA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIPOXYGENASE INHIBITORS; MALE; MEMBRANE PROTEINS; MESOCRICETUS; MOUTH NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; UP-REGULATION;

EID: 16344393138     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1684     Document Type: Article

References (45)

1. Mackenzie J, Ah-See K, Thakker N, et al. Increasing incidence of oral cancer amongst young persons: what is the etiology? Oral Oncol 2000;36:387-9.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-19.
3. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002;24:165-80.
4. El-Hakim IE, Langdon JD. Arachidonic acid cascade and oral squamous cell carcinoma. Clin Otolarygol 1991;16:563-73.
5. Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, La Vecchia C. Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 2003;88:672-4.
6. Sudbo J, Ristimaki A, Sondresen JE, et al. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003;39:497-505.
7. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 2003;9:1885-97.
8. Jeng JH, Wang YJ, Chiang BL, et al. Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-α production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis 2003;24:1301-15.
9. Yang CY, Meng CL, Liao CL, Wong PY. Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines. Prostaglandins Other Lipid Mediat 2003;72:115-30.
10. Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001;61:1451-6.
11. Cornwall H, Odukoya O, Shklar G. Oral mucosal tumor inhibition by ibuprofen. J Oral Maxillofac Surg 1983;41:795-800.
12. Franklin CD, Craig GT. The effect of indomethacin on tumor regression in DMBA-induced epithelial neoplasia of hamster cheek pouch mucosa. Oral Surg Oral Med Oral Pathol 1987;63:335-9.
13. Gould AR, Miller RL, Grant FT, Perry DA. Indomethacin and 7,12-dimethylbenz(a)anthracene-induced carcinogenesis in the hamster buccal pouch. J Oral Pathol 1985;14:398-404.
14. Ondrey FG, Juhn SK, Adams GL. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106:129-34.
15. Mohammad AR, Sastry KA, Ruprecht A, Turner JE, Batarfi M, Khalifa R. Effect of indomethacin in inhibition of DMBA chemical carcinogenesis. J Oral Med 1986;41:158-63.
16. Perkins TM, Shklar G. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg 1982;53:170-7.
17. El-Hakim IE, Langdon ID, Zakrzewski JT, Costello JF. Leukotriene B4 and oral cancer. Br J Oral Maxillofac Surg 1990;28:155-9.
18. Peters-Golden M, Brock TG. 5-Lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids 2003;69:99-109.
19. Funk CD, Chen XS, Johnson EN, Zhao L. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat 2002;68-69:303-12.
20. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001;91:737-43.
21. Hennig R, Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002;161:421-8.
22. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003;124:57-70.
23. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H, Nakatani T. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 2003;170:1994-9.
24. Yoshimura R, Matsuyama M, Mitsuhashi M, et al. Relationship between lipoxygenase and human testicular cancer. Int J Mol Med 2004;13:389-93.
25. Chen X, Wang S, Wu N, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma, and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004;10:6703-9.
26. Steele VE, Holmes CA, Hawk ET, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999;8:467-83.
27. Gunning WT, Kramer PM, Steele VE, Pereira MA. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res 2002;62:4199-201.
28. Jiang H, Yamamoto S, Kato R. Inhibition of two-stage skin carcinogenesis as well as complete skin carcinogenesis by oral administration of TMK688, a potent lipoxygenase inhibitor. Carcinogenesis 1994;15:807-12.
29. Wenger FA, Kilian M, Achucarro P, et al. Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 2002;2:54-60.
30. Wenger FA, Kilian M, Bisevac M, et al. Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. Clin Exp Metastasis 2002;19:681-7.
31. Li N, Chen X, Josephson Y, et al. Inhibition of 7,12-dimethylbenz[a] anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 2002;23:1307-13.
32. Pingdborg J, Reichart P, Smith C, van der Wall I. World Health Organization. International histological classification of tumors: histological typing of cancer and precancer of oral mucosa. 2nd ed. Berlin, Heidelberg: Springer; 1997. p. 1-40.
33. Werz O. 5-lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 2002;1:23-44.
34. Laska EM, Meisner M, Siegel C. Simple designs and model-free tests for synergy. Biometrics 1994;50:834-41.
35. Puignero V, Queralt J. Effect of topically applied cyclooxygenase-2- selective inhibitors on arachidonic acid- and tetradecanoylphorbol acetate-induced dermal inflammation in the mouse. Inflammation 1997;21:431-42.
36. Rao TS, Yu SS, Djuric SW, Isakson PC. Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor. J Lipid Mediat Cell Signal 1994;10:213-28.
37. Wiese FW, Thompson PA, Kadlubar FF. Carcinogen substrate specificity of human Cox-1 and Cox-2. Carcinogenesis 2001;21:5-10.
38. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A 2003;99:12483-8.
39. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165:229-35.
40. Gavett SH, Madison SL, Chulada PC, et al. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 1999;104:721-32.
41. Nakamura Y, Kozuka M, Naniwa K, et al. Arachidonic acid cascade inhibitors modulate phorbol ester-induced oxidative stress in female ICR mouse skin: differential roles of 5-lipoxygenase and cyclooxygenase-2 in leukocyte infiltration and activation. Free Radic Biol Med 2003;35:997-1007.
42. Carter GW, Young PR, Albert DH, et al. 5-Lipoxygenase inhibitory activity of Zileuton. J Pharmacol Exp Ther 1991;256:929-37.
43. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-40.
44. Wilgus TA, Koki AT, Zweifel BS, et al. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003;38:49-58.
45. Wang Z, Polavaram R, Shapshay SM. Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett 2003;198:53-8.